Overview

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Status:
RECRUITING
Trial end date:
2031-12-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
Phase:
PHASE3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
guselkumab